| Title | Claps | Level | Year | L/Y |
|---|---|---|---|---|
|
Response to letters regarding article, "prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS Liberté paclitaxel-eluting coronary stent placement".
10 auth. K. Garratt, W. Weaver, R. Jenkins, Thomas K. Pow, L. Mauri, D. Kereiakes, ...
Drs Jeger and Pfisterer have asked 2 important questions: Does the increase in ischemic events we reported after cessation of dual-antiplatelet therapy (DAPT) in the TAXUS Libertē Post-Approval Study (TL-PAS) patients1 reflect a rebound risk specifi…
Drs Jeger and Pfisterer have asked 2 important questions: Does the increase in ischemic events we reported after cessation of dual-antiplatelet therapy (DAPT) in the TAXUS Libertē Post-Approval Study (TL-PAS) patients1 reflect a rebound risk specific to the TAXUS Liberte paclitaxel-eluting stent that may not apply to other drug-eluting stents, and did use of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) bleeding definitions underestimate important bleeding in patients treated with prasugrel? Drs Shah and Buch shared their concern about bleeding, and also wondered whether the use of intravascular ultrasound (IVUS) to perfect stent placement might have diminished the need for prolonged DAPT.
Comparative studies have reported higher rates of stent thrombosis with the TAXUS Liberte paclitaxel-eluting stent …
Published in
Circulation
|
0
|
0 | 2015 |
Social Media Posts